Detection of p53 auto-antibodies in the sera of breast cancer patients with a new recurrence using an ELISA assay. Does a correlation with the recurrence free interval exist?

European Journal of Gynaecological Oncology

Volumn 17, Issue 3, 1996, Pages 192-199

  Regidor, P A ^a   Regidor, M ^a   Callies, R ^a   Schindler, A E ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Auto antibodies against mutant p53; Breast cancer recurrences; Mutant p53; Serum ELISA assay

Indexed keywords

AUTOANTIBODY; PROTEIN P53;

ANTIBODY DETECTION; ARTICLE; BREAST CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; PROGNOSIS; RECURRENT CANCER; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

AUTOANTIBODIES; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029937504     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Lane D. P., Crawford L. V.: "T antigen is bound to a host protein in SV40-transformed cells". Nature, 1979, 278, 261.
2. Mercer W. E., Avignolo C., Baserga R.: "Role of the p53 protein in cell proliferation as studied by microinjection of monoclonal antibodies". Mol. Cell. Biol., 1984, 4, 276.
3. Munroe D. G., Rovinski B., Bernstein A., Benchimol S.: "Loss of a highly conserved domain on p53 as a result of gene deletions during Friend virus-induced erythroleukemia". Oncogene, 1988, 2, 621.
4. Finlay C. A., Hinas P. W., Tan T. H., Eliyanu D., Oren M., Levine A. J.: "Activating mutations for transformation by p53 produce a gene product that forms an hsc-70-p53 complex with an altered half-life". Mol. Cell. Biol., 1988, 8, 531.
5. Finlay C. A., Hinds P. H., Levine A. J.: "The p53 proto-oncogene can act as a suppressor of transformation". Cell., 1989, 57, 1083.
6. Burkart C.: "Das Tumorsupressorprotein p53". Deutsches Ärzteblatt 1994, Heft 13 (27), 679.
7. Lane D. P.: "On the expression of the p53 protein in human cancer". Mol. Biol. Rep., 1994, 19, 23.
8. Kastan M. B., Zhan Q., El-Deiry W. K., Carrier F. Jacks T., Walsh W V., Plunkett B. S., Vogelstein B., Fornace A. J.: "A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia". Cell., 1992, 71, 587.
9. Lu X., Lane D. P.: "Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes?". Cell., 1993, 75, 765.
10. Yonish R. E., Resnitzky D., Lotem J., Sachs L., Kimchi A., Oren M.: "Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6". Nature, 1991, 352, 345.
11. Martinez J., Georgoff I., Martinez J., Levine A. J.: "Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein". Genes, 1991, 5, 151.
12. Hall P. A., McKee P H., Menage M.d.P., Dover R., Lane D. P.: "High levels of p53 protein in UV-irradiated normal human skin". Oncogene, 1993, 8, 203.
13. Scheffner M., Werness B. A., Hulbregtsc J. M., Levine A. J., Howley P. M.: "The E6 oncoprotein encoded by human papillomavirus types 16 and and 18 promotes the degradation of p53". Cell , 1990, 63, 1129.
14. Scheffner M., Munger K., Byrne J. C., Howley P. M.: "The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines". Proc. Natl. Acad. Sci., 1991, 88, 5523.
15. Oliner J. D., Pietenpol J. A., Kinzler K. W., Thiagalingam S., Gyuris J., Kinzler K. W., Vogelstein B.: "Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53". Nature, 1993, 362, 857.
16. Schimmelpenning H., Erikson E. T., Zetterberg A., Aner G. U.: "Association of immunohistochemical p53 tumour suppressor gene protein overexpression with prognosis in highly proliferative human mammary adenocarcinomas". World J. Surg., 1994, 18, 827.
17. Elledge R. M., Clark G. M., Fuqua S. A., Yu Y. Y., Allred D. C.: "p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer". Cancer Res., 1994, 54, 3752.
18. Marxsen J., Schmiegel W., Roder C., Harder R., Juhl H., Henne-Bruns D., Kremer B., Kalthoff H.: "Detection of the anti-p53 antibody response in malignant and benign pancreatic disease"; Br. J. Cancer, 1994, 70, 1031.
19. Angelopoulou K., Diamandis E. P., Sutherland D. J., Kellen J.A., Bunting P. S.: "Prevalence of serum antibodies against the p53 tumour suppressor gene protein in various cancers". Int. J. Cancer, 1994, 58, 480.
20. Green J. A., Mudenda B., Jenkins J., Leinster S. J., Tarunina M., Green B., Robertson L.: "Serum p53 auto-antibodies: incidence in familial breast cancer". Eur. J. Cancer, 1994, 30A, 580.
21. Scatchard L. A., et al.: "The attraction of proteins for small molecules and ions". Ann N. Y. Acad. Sci, 1949, 57, 660.
22. Lowry O. H., et al: "Protein measurement with the Folin reagent". J. Biol. Chem., 1951, 193, 265.
23. SAS Institute Inc. SAS User's Guide Basics, 1985. Version 5 Edition. Cary, NC: SAS Institute Inc., 1290.
24. Käsar O., Iklé F. A., Hirsch H. A.: "Atlas der gynäkologischen Operationen". 1983, Auflage Stuttgart: New York: Thieme, 1823.
25. Levine A. J., Momand J., Finlay C. A.: "The p53 tumour suppressor gene". Nature, 1991, 351, 453.
26. Hollstein M., Sidransky D., Vogelstein B., et al.: "p53 mutations in human cancers". Science, 1991, 253, 49.
27. Bartek J., Bartkova J., Vorresek B., et al.: "Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies". Oncogene, 1991, 6, 1699.
28. Cossman J., Schlegel R.: "p53 in the diagnosis of human neoplasia". Natl. Cancer Inst., 1991, 83, 980.
29. Boyd J. A., Barrett J. C.: "Tumour suppressor genes: possible functions in the negative regulation of cell proliferation". Mol. Carcinog., 1990, 3, 325.
30. Gamble J., Milner J.: "Evidence that immunological variants of p53 represent alternative protein conformations". Virology, 1988, 162, 452.
31. Davidoff A. M., Iglehart J. D., Marks J. R.: "Immune response to p53 is dependant upon p53/HSP70 complexes in breast cancers". Proc. Natl. Acad. Sci. USA, 1992, 89, 3439.
32. Huober J., Costa S. D., Zentgraf H., Bastert G.: "Serumantikörper gegen das Tumorsupressorprotein p53 beim Mamma- und Ovarialkarzinom". Arch. Gynecol. Obstet., 1994, 255, Supplement 1, 150.